Immunosuppressive treatment as a risk factor for the occurrence of clostridium difficile infection (CDI);Immunsuppressive Behandlung als Risikofaktor für das Auftreten einer Clostridium-difficile-Infektion (CDI)

Zeitschrift fur Gastroenterologie

Volumn 51, Issue 11, 2013, Pages 1251-1258

  Lubbert C ^a,b   Johann, C ^a   Kekule A S ^a   Worlitzsch, D ^a   Weis, S ^b   Mossner J ^b   Behl, S ^a   Seufferlein, T ^a,c  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

C. difficile Infection (CDI); C. difficile associated diarrhoea (CDAD); Clostridium difficile; immunsuppression; infectious colitis; pseudomembranous colitis

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; OBSERVATIONAL STUDY; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GERMANY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887853374     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0033-1335505     Document Type: Article

References (33)

1. Hall I. C., O'Toole E. Intestinal flora in newborn infants with description of a new pathogenic anaerobe. Am J Dis Child: 1935; 49 390 402
2. Bartlett J. G., Chang T. W., Gurwith M. et al. Antibiotic-associated pseudomembranous colitis due to toxinproducing clostridia. N Engl J Med: 1978; 298 531 534 (Pubitemid 8295586)
3. Larson H. E., Price A. B., Honour P. et al. Clostridium difficile and the etiology of pseudomembranous colitis. Lancet: 1978; 1 1063 1066 (Pubitemid 8356366)
4. Kyne L., Hamel M. B., Polavaram R. et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis: 2002; 34 346 353 (Pubitemid 34062235)
5. Vonberg R. P., Reichardt C., Behnke M. et al. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infection: 2008; 70 15 20
6. Bauer M. P., Notermans D. W., van Benthem B. H. et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet: 2011; 377 63 73
7. Grünewald T., Kist M., Mutters R. et al. Clostridium difficile-Infektion. Dtsch Med Wochenschr: 2010; 135 699 703
8. Reichardt C., Chaberny I. F., Kola A. et al. Dramatischer Anstieg von Clostridium-difficile-assoziierter Diarrhö in Deutschland. Dtsch Med Wochenschr: 2007; 132 223 228 (Pubitemid 46395769)
9. Burckhardt F., Friedrich A., Beier D. et al. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis: 2008; 14 691 692 (Pubitemid 351520889)
10. Ackermann G. Clostridium difficile - Aktueller Stand. Mikrobiologe: 2004; 14 123 129
11. Raveh D., Rabinowitz B., Breuer G. S. et al. Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea. Int J Antimicrob Agents: 2006; 28 231 237 (Pubitemid 44223986)
12. Robert Koch-Institut. Ratgeber Infektionskrankheiten - Merkblätter für Ärzte: Clostridium difficile. Epidemiol Bull: 2009; 24 233 239
13. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect: 2009; 58 403 410
14. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut (RKI) Anforderungen an die Hygiene bei der medizinischen Versorgung von immunsupprimierten Patienten - Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut (RKI). Bundesgesundheitsbl: 2010; 53 357 388
15. Bodey G., Buckley M., Sathe Y. et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med: 1966; 64 328 340
16. Crawford J., Dale D. C., Lyman G. H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer: 2004; 100 228 237 (Pubitemid 38063629)
17. Morteau O. et al. Genetic deficiency in the chemokine receptor CCR1 protects against acute Clostridium difficile toxin A enteritis in mice. Gastroenterology: 2002; 122 725 733 (Pubitemid 34173824)
18. Paredes-Sabja D., Sarker M. E. Adherence of Clostridium difficile spores to Caco-2 cells in culture. J Med Microbiol: 2012; 61 1208 1218
19. Anand A., Glatt A. E. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis: 1993; 17 109 113 (Pubitemid 23197574)
20. Cudmore M. A., Silva J. Jr, Fekety R. et al. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med: 1982; 142 333 335 (Pubitemid 12180808)
21. Blot E., Escande M. C., Besson D. et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect: 2003; 53 187 192 (Pubitemid 38002053)
22. Sharma A. K., Holder F. E. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Clin Infect Dis: 1998; 27 1540 1541 (Pubitemid 29242443)
23. Rubin M. S., Bodenstein L. E., Kent K. C. Severe Clostridium difficile colitis. Dis Colon Rectum: 1995; 38 350 354
24. Frost F., Craun G. F., Calderon R. L. Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease. Emerg Infect Dis: 1998; 4 619 625 (Pubitemid 28553686)
25. Das R., Feuerstadt P., Brandt L. J. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease. Am J Gastroenterol: 2010; 105 2040 2049
26. Collini P. J., Bauer M., Kuijper E. et al. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect: 2012; 64 131 147
27. West M., Pirenne J., Chavers B. et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant: 1999; 13 318 323 (Pubitemid 29392622)
28. Dallal R. M., Harbrecht B. G., Boujoukas A. J. et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg: 2002; 235 363 372 (Pubitemid 34183887)
29. Gavazzi G., Mallaret M. R., Couturier P. et al. Differences Between Young-Old, Old And Old-Old Patients. Journal of the American Geriatric Society: 2002; 50 1667 1673 (Pubitemid 35192538)
30. Apostolopoulou E., Raftopoulos V., Terzis K. et al. Infection Probability Score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. Eur J Oncol Nurs: 2011; 15 404 409
31. Dial S., Delaney J. A., Barkun A. N. et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA: 2005; 294 2989 2995 (Pubitemid 41817660)
32. DuPont H. L. The search for effective treatment of Clostridium difficile infection. N Engl J Med: 2011; 364 473 475
33. Lo V. A., Zacur G. M. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol: 2012; 28 1 9